Infectious diseases now · 2026
Ecotoxicity and carbon footprint of commonly used antibiotics: Moving towards environmentally sustainable use.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Réveillon Istin Mathilde, Pierre Valérie, Beaumont Anne-Lise, Taillemite Sébastien, Nyssen Nicolas, Bounoure Fréderic, Bougle Céline, Mondain Véronique, Piednoir Emmanuel, Hocquet Didier
Аннотация
INTRODUCTION: The environmental impact of antibiotics is described as high, although it has never been precisely assessed. We evaluated the environmental impact of some antibiotics.
METHODS: Environmental impact was measured by (i) carbon footprint (CF) through Life Cycle Assessment and (ii) ecotoxicity, assessed by the Risk Quotients for the risk of antimicrobial resistance development (RQ-R), calculated from median environmental concentrations and theoretical Predicted No-Effect Concentrations (PNECs).
RESULTS: Production of antibiotics in Europe reduces CF compared to production in Asia. Intravenous (IV) levofloxacin has a higher CF than per os levofloxacin. IV push has a lower CF than IV drip administration. Ceftriaxone and azithromycin have respectively a lower CF than cefotaxime and clarithromycin. Although co-trimoxazole CF is higher than that of fluoroquinolones, its RQ-R is lower.
CONCLUSION: Although discrepancies between CF and eco-toxicity limit recommendations, these two parameters may guide decisions to reduce environmental footprint in a One-Health approach.
METHODS: Environmental impact was measured by (i) carbon footprint (CF) through Life Cycle Assessment and (ii) ecotoxicity, assessed by the Risk Quotients for the risk of antimicrobial resistance development (RQ-R), calculated from median environmental concentrations and theoretical Predicted No-Effect Concentrations (PNECs).
RESULTS: Production of antibiotics in Europe reduces CF compared to production in Asia. Intravenous (IV) levofloxacin has a higher CF than per os levofloxacin. IV push has a lower CF than IV drip administration. Ceftriaxone and azithromycin have respectively a lower CF than cefotaxime and clarithromycin. Although co-trimoxazole CF is higher than that of fluoroquinolones, its RQ-R is lower.
CONCLUSION: Although discrepancies between CF and eco-toxicity limit recommendations, these two parameters may guide decisions to reduce environmental footprint in a One-Health approach.